207 related articles for article (PubMed ID: 29049452)
21. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
[TBL] [Abstract][Full Text] [Related]
22. Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer.
Shiota M; Endo S; Tsukahara S; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38688318
[TBL] [Abstract][Full Text] [Related]
23.
Zein J; Gaston B; Bazeley P; DeBoer MD; Igo RP; Bleecker ER; Meyers D; Comhair S; Marozkina NV; Cotton C; Patel M; Alyamani M; Xu W; Busse WW; Calhoun WJ; Ortega V; Hawkins GA; Castro M; Chung KF; Fahy JV; Fitzpatrick AM; Israel E; Jarjour NN; Levy B; Mauger DT; Moore WC; Noel P; Peters SP; Teague WG; Wenzel SE; Erzurum SC; Sharifi N
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2187-2193. PubMed ID: 31932420
[TBL] [Abstract][Full Text] [Related]
24. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Chen EJ; Sowalsky AG; Gao S; Cai C; Voznesensky O; Schaefer R; Loda M; True LD; Ye H; Troncoso P; Lis RL; Kantoff PW; Montgomery RB; Nelson PS; Bubley GJ; Balk SP; Taplin ME
Clin Cancer Res; 2015 Mar; 21(6):1273-80. PubMed ID: 25320358
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.
Yamada T; Nakayama M; Shimizu T; Nonen S; Nakai Y; Nishimura K; Fujio Y; Okuyama A; Azuma J; Nonomura N
Int J Clin Oncol; 2013 Aug; 18(4):711-7. PubMed ID: 22714708
[TBL] [Abstract][Full Text] [Related]
26. Germline variants and response to systemic therapy in advanced prostate cancer.
Johnson E; Nussenzveig R; Agarwal N; Swami U
Pharmacogenomics; 2020 Jan; 21(1):75-81. PubMed ID: 31849283
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.
Shiota M; Fujimoto N; Sekino Y; Tsukahara S; Nagakawa S; Takamatsu D; Abe T; Kinoshita F; Ueda S; Ushijima M; Matsumoto T; Kashiwagi E; Inokuchi J; Uchiumi T; Oda Y; Eto M
Andrologia; 2022 Feb; 54(1):e14307. PubMed ID: 34747051
[TBL] [Abstract][Full Text] [Related]
28. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
29. Association Between Adrenal-Restrictive HSD3B1 Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer.
McManus JM; Vargas R; Bazeley PS; Schumacher FR; Sharifi N
JNCI Cancer Spectr; 2022 Sep; 6(5):. PubMed ID: 35947687
[TBL] [Abstract][Full Text] [Related]
30. Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT.
Handy WF; Schmidt KT; Price DK; Figg WD
Cancer Biol Ther; 2020 Sep; 21(9):782-784. PubMed ID: 32791030
[TBL] [Abstract][Full Text] [Related]
31. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.
Chen WS; Feng EL; Aggarwal R; Foye A; Beer TM; Alumkal JJ; Gleave M; Chi KN; Reiter RE; Rettig MB; Evans CP; Small EJ; Sharifi N; Zhao SG
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):316-323. PubMed ID: 31745256
[TBL] [Abstract][Full Text] [Related]
32. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C
Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278
[TBL] [Abstract][Full Text] [Related]
33. ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.
Peltola KJ; Bono P; Jones RH; Vjaters E; Nykänen P; Vuorela A; Oksala R; Pohjanjousi P; Mustonen MVJ; Fizazi K; Massard C
Eur Urol Focus; 2020 Jan; 6(1):63-70. PubMed ID: 30194031
[TBL] [Abstract][Full Text] [Related]
34. The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Rehman OU; Nadeem ZA; Fatima E; Akram U; Imran H; Husnain A; Nadeem A; Rasheed W
Clin Genitourin Cancer; 2024 Apr; 22(2):483-490.e5. PubMed ID: 38296679
[TBL] [Abstract][Full Text] [Related]
35. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
36. Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation.
Cui D; Li J; Zhu Z; Berk M; Hardaway A; McManus J; Chung YM; Alyamani M; Valle S; Tiwari R; Han B; Goudarzi M; Willard B; Sharifi N
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 37009898
[TBL] [Abstract][Full Text] [Related]
37. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
[TBL] [Abstract][Full Text] [Related]
38. CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
Crucitta S; Del Re M; Paolieri F; Bloise F; Sbrana A; Sammarco E; Mercinelli C; Cucchiara F; Fontanelli L; Galli L; Danesi R
Cancer Chemother Pharmacol; 2020 Oct; 86(4):527-533. PubMed ID: 32945940
[TBL] [Abstract][Full Text] [Related]
39. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
[TBL] [Abstract][Full Text] [Related]
40. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Binder M; Zhang BY; Hillman DW; Kohli R; Kohli T; Lee A; Kohli M
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]